Dr. Goetz on the Clinical Significance of Lasofoxifene in ER+/HER2- Breast Cancer
October 7th 2022Matthew P. Goetz, MD, discusses the clinical significance of the phase 2 ELAINE-1 trial of lasofoxifene in patients with ESR1-mutated, estrogen receptor-positive/HER2-negative metastatic breast cancer.
Read More
Dr. Goetz on Adjuvant Capecitabine Following Neoadjuvant Chemotherapy and Surgery
December 10th 2015Matthew Goetz, MD, medical oncologist, professor of Oncology, associate professor of Pharmacology, andprofessor of Pharmacology at Mayo Clinic, discusses a phase III study looking at capecitabine (Xeloda) in patients with residual breast cancer following neoadjuvant chemotherapy and surgery.
Read More